Future Treatment for Malaria

WHY ActRx TriAct Plus®?

A child dies every 30 seconds from Malaria. Estimates now suggest that more than 500 million people worldwide have the disease, making it the number one killer in the world today. Morbidity reports indicate that most of the Malaria-diagnosed deaths occurs with pregnant women and children. While the disease has reportedly been eradicated in the US, it continues to proliferate in tropical environments throughout the world, most prominently in Africa, Asia, Central and South America.

ActRx TriAct Plus® is the newest proprietary, patent-pending ACT formulation, designed for the treatment of Malaria, both severe and uncomplicated, now undergoing clinical trials by the ActRx international medical research team under the Sponsorship of The ActRx Foundation.